Here we report that this novel HDAC inhibitor potently inhibited cell growth/proliferation in human tumor cell lines from both solid and hematologic origin, and significantly suppressed tumor growth in several xenograft models after oral daily delivery, thus suggesting a putative application against some tumor subsets in patients. The gene discussed is HDAC9; the disease is neoplasm.